Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J P Pinto

Showing results (51-60 of 60) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 60 results.
Journal of Medicinal Chemistry|December 4, 2003
Discovery of 1-(2-aminomethylphenyl)-3-trifluoromethyl-N- [3-fluoro-2'-(aminosulfonyl)[1,1'-biphenyl)]-4-yl]-1H-pyrazole-5-carboxyamide (DPC602), a potent, selective, and orally bioavailable factor Xa inhibitor(1)James R Pruitt, Donald J P Pinto, Robert A Galemmo, et al.
Journal of Medicinal Chemistry|October 3, 2003
Structure-based design of novel guanidine/benzamidine mimics: potent and orally bioavailable factor Xa inhibitors as novel anticoagulantsPatrick Y S Lam, Charles G Clark, Renhua Li, et al.
Bioorganic & Medicinal Chemistry Letters|April 22, 2008
Structure-activity relationships of anthranilamide-based factor Xa inhibitors containing piperidinone and pyridinone P4 moietiesJames R Corte, Tianan Fang, Donald J P Pinto, et al.
Bioorganic & Medicinal Chemistry Letters|May 30, 2006
1-[3-Aminobenzisoxazol-5'-yl]-3-trifluoromethyl-6-[2'-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1,1']-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one (BMS-740808) a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor XaDonald J P Pinto, Michael J Orwat, Mimi L Quan, et al.
Bioorganic & Medicinal Chemistry Letters|March 3, 2015
Structure-based design of inhibitors of coagulation factor XIa with novel P1 moietiesDonald J P Pinto, Joanne M Smallheer, James R Corte, et al.
Bioorganic & Medicinal Chemistry Letters|December 26, 2015
Novel phenylalanine derived diamides as Factor XIa inhibitorsLeon M Smith, Michael J Orwat, Zilun Hu, et al.
Bioorganic & Medicinal Chemistry Letters|August 26, 2019
Structure based design of macrocyclic factor XIa inhibitors: Discovery of cyclic P1 linker moieties with improved oral bioavailabilityCharles G Clark, Karen A Rossi, James R Corte, et al.
Journal of Medicinal Chemistry|October 28, 2017
Discovery of a Parenteral Small Molecule Coagulation Factor XIa Inhibitor Clinical Candidate (BMS-962212)Donald J P Pinto, Michael J Orwat, Leon M Smith, et al.
Journal of Medicinal Chemistry|September 8, 2021
Discovery of Milvexian, a High-Affinity, Orally Bioavailable Inhibitor of Factor XIa in Clinical Studies for Antithrombotic TherapyAndrew K Dilger, Kumar B Pabbisetty, James R Corte, et al.
Journal of Medicinal Chemistry|December 14, 2019
Potent, Orally Bioavailable, and Efficacious Macrocyclic Inhibitors of Factor XIa. Discovery of Pyridine-Based Macrocycles Possessing Phenylazole Carboxamide P1 GroupsJames R Corte, Donald J P Pinto, Tianan Fang, et al.
Pageof 6

Showing results (51-60 of 60) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 60 results.
Journal of Medicinal Chemistry|December 4, 2003
Discovery of 1-(2-aminomethylphenyl)-3-trifluoromethyl-N- [3-fluoro-2'-(aminosulfonyl)[1,1'-biphenyl)]-4-yl]-1H-pyrazole-5-carboxyamide (DPC602), a potent, selective, and orally bioavailable factor Xa inhibitor(1)James R Pruitt, Donald J P Pinto, Robert A Galemmo, et al.
Journal of Medicinal Chemistry|October 3, 2003
Structure-based design of novel guanidine/benzamidine mimics: potent and orally bioavailable factor Xa inhibitors as novel anticoagulantsPatrick Y S Lam, Charles G Clark, Renhua Li, et al.
Bioorganic & Medicinal Chemistry Letters|April 22, 2008
Structure-activity relationships of anthranilamide-based factor Xa inhibitors containing piperidinone and pyridinone P4 moietiesJames R Corte, Tianan Fang, Donald J P Pinto, et al.
Bioorganic & Medicinal Chemistry Letters|May 30, 2006
1-[3-Aminobenzisoxazol-5'-yl]-3-trifluoromethyl-6-[2'-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1,1']-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one (BMS-740808) a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor XaDonald J P Pinto, Michael J Orwat, Mimi L Quan, et al.
Bioorganic & Medicinal Chemistry Letters|March 3, 2015
Structure-based design of inhibitors of coagulation factor XIa with novel P1 moietiesDonald J P Pinto, Joanne M Smallheer, James R Corte, et al.
Bioorganic & Medicinal Chemistry Letters|December 26, 2015
Novel phenylalanine derived diamides as Factor XIa inhibitorsLeon M Smith, Michael J Orwat, Zilun Hu, et al.
Bioorganic & Medicinal Chemistry Letters|August 26, 2019
Structure based design of macrocyclic factor XIa inhibitors: Discovery of cyclic P1 linker moieties with improved oral bioavailabilityCharles G Clark, Karen A Rossi, James R Corte, et al.
Journal of Medicinal Chemistry|October 28, 2017
Discovery of a Parenteral Small Molecule Coagulation Factor XIa Inhibitor Clinical Candidate (BMS-962212)Donald J P Pinto, Michael J Orwat, Leon M Smith, et al.
Journal of Medicinal Chemistry|September 8, 2021
Discovery of Milvexian, a High-Affinity, Orally Bioavailable Inhibitor of Factor XIa in Clinical Studies for Antithrombotic TherapyAndrew K Dilger, Kumar B Pabbisetty, James R Corte, et al.
Journal of Medicinal Chemistry|December 14, 2019
Potent, Orally Bioavailable, and Efficacious Macrocyclic Inhibitors of Factor XIa. Discovery of Pyridine-Based Macrocycles Possessing Phenylazole Carboxamide P1 GroupsJames R Corte, Donald J P Pinto, Tianan Fang, et al.
Pageof 6